Evaxion Biotech A/S (EVAX)
Evaxion Biotech A/S at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Evaxion Biotech A/S (EVAX) is a Biotechnology company based in DK with a market capitalization of $18.7M. Revenue grew 125.1% year-over-year and free cash flow was negative at -$6.7M. This page tracks EVAX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
DK · 46 employees · IPO Feb 5, 2021
Valuation
Valuation & price
$4.04as of May 26, 2026· -63.3% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.10
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$18.7M
Market cap
125.1%
Revenue growth (YoY)
100.0%
Gross margin
-$6.7M
Free cash flow (USD)
-$15.7M
Net debt
Net cash position
497.3%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2018 → 2025
Free cash flow by year
2018 → 2025
Gross margin by year
2023 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 6-K filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 6-K filingJul 17, 2026Filing
Clinical Data Presentation
- 6-K filingJul 13, 2026Filing
Preclinical Data Presentation
- 6-K filingJul 1, 2026Filing
Press Release
- 6-K filingJun 12, 2026Filing
Award Received
- 6-K filingJun 11, 2026Filing
Preclinical Data Presentation
- 6-K filingMay 12, 2026Filing
Data Presentation Announcement
- Annual reportMay 7, 2026Filing
Annual Report Filed
- Annual reportMay 4, 2026Filing
Annual Report Filed
- 6-K filingApr 27, 2026Filing
Management Change
- Annual reportApr 22, 2026Filing
Annual Report Filed
Questions
Frequently asked questions
What is Evaxion Biotech A/S's market cap?
Evaxion Biotech A/S (EVAX) has a market capitalization of $18.7M.
What is EVAX's P/E ratio?
A meaningful P/E ratio is not available for EVAX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is EVAX's price-to-book (P/B) ratio?
EVAX trades at 1.10 times book value per share.
Are insiders buying EVAX stock?
SEC Form 4 filings show no open-market insider buys at Evaxion Biotech A/S in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.